Furthermore, CGA dose-dependently decreased the expression levels of TNF-α, TNFR-1, Fasl, Fas, Caspase-8, Bax, Caspase-3, NF-kB, IL-6, and P53 in liver tissues, while it increased Bcl-2 expression, thereby alleviating NAFLD symptoms caused by a high-fat diet, reducing hepatocyte apoptosis, and providing a protective effect on hepatocytes [51]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.